Vaxcyte, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PCVX research report →
Companyvaxcyte.com
Vaxcyte, Inc. , a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia.
- CEO
- Grant E. Pickering
- IPO
- 2020
- Employees
- 414
- HQ
- San Carlos, CA, US
Price Chart
Valuation
- Market Cap
- $6.81B
- P/E
- -6.95
- P/S
- 0.00
- P/B
- 2.20
- EV/EBITDA
- -7.05
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -32.51%
- ROIC
- -34.98%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-766,628,000 · -65.25%
- EPS
- $-5.63 · -48.16%
- Op Income
- $-923,675,000
- FCF YoY
- -40.89%
Performance & Tape
- 52W High
- $65.00
- 52W Low
- $29.08
- 50D MA
- $57.05
- 200D MA
- $47.25
- Beta
- 1.30
- Avg Volume
- 1.38M
Get TickerSpark's AI analysis on PCVX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 1, 26 | Wassil Jim | sell | 2,250 |
| Apr 7, 26 | Cowan Elvia | other | 3,000 |
| Apr 7, 26 | Cowan Elvia | other | 3,000 |
| Apr 7, 26 | Cowan Elvia | sell | 3,000 |
| Apr 1, 26 | Wassil Jim | sell | 1,412 |
| Apr 1, 26 | Wassil Jim | sell | 838 |
| Mar 17, 26 | Cowan Elvia | sell | 1,487 |
| Mar 17, 26 | Cowan Elvia | sell | 405 |
| Mar 9, 26 | Dhaliwal Harpreet S. | other | 604 |
| Mar 9, 26 | PICKERING GRANT | other | 3,685 |
Our PCVX Coverage
We haven't published any research on PCVX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate PCVX Report →